DOD Ovarian Cancer Idea Development Award

The summary for the DOD Ovarian Cancer Idea Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD Ovarian Cancer Idea Development Award: The OCRP Idea Development Award mechanism was offered in FY02 through FY06 to support innovative research in ovarian cancer. During this time, 616 proposals have been received and 51 OCRP Idea Development Awards have been made. The OCRP Idea Development Award supports high impact, innovative research that will drive the field forward. NEW FOR FY08 - This award seeks proposals from all areas of ovarian cancer research. However, for FY08, this award encourages proposals that address critical needs of the ovarian cancer community in the following areas: . Identification and characterization of early changes associated with ovarian cancer. . Identification and characterization of ovarian cancer stem cells. . The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. Important aspects of the Idea Development Award are as follows: 1. Impact: The proposed research should have a significant impact on the concepts or methods that drive the field of ovarian cancer research. The proposed research is expected to make original and important contributions to the goal of advancing ovarian cancer research and/or ovarian cancer patient care. 2. Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. Research may be innovative in study concept, research methods or technology, clinical interventions, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative. Examples of research that are not innovative and that will not be considered for funding under this mechanism include: Exploring a previously tested hypothesis in a different cell line; using a published series of in vitro assays to further characterize a model system; and incorporating known biomarkers into in vitro or clinical models of ovarian cancer. 3. Preliminary Data: Preliminary data relevant to the proposed project, but not necessarily in ovarian cancer, are required. 4. Proposals Involving Clinical Trials: If a proposal requests support for a clinical trial, the PI is required to submit a clinical protocol in addition to the proposal by the proposal receipt deadline. Such trials must have a clinical coordinator who has sufficient time dedicated to the project to carry out the record keeping, coordination, and/or other administrative duties the project entails. The protocol will be reviewed separately. Clinical trials must begin within 12 months of the award date. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) is required, additional time may be granted. However, preference will be given to proposals that have U.S. Food and Drug Administration (FDA) approval at the time the award is made. 5. Optional Non-traditional Collaboration (NEW FOR FY08): The FY08 OCRP Idea Development Award strongly supports collaborative research between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional collaboration is to increase the leveraging of resources in the ovarian cancer research community. The collaborator in this optional non-traditional collaboration must contribute at least 10% level of effort to the project (as reflected in the budget) and provide intellectual input and research resources (e.g., supplies, reagents, equipment, personnel), or intellectual input and financial resources. Collaborations that bring new perspectives from other disciplines or bring new investigators into the ovarian cancer field are also strongly encouraged. Consequently, if the PI does not have experience in ovarian cancer, then the collaborator must have ovarian cancer experience, as demonstrated through publications in the field, funding history, and/or patient care.